Management of Cutaneous Lupus Erythematosus

  • Jeffrey P. Callen


Topical Corticosteroid Mycophenolate Mofetil Triamcinolone Acetonide Cefuroxime Axetil Cutaneous Lupus Erythematosus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Atra E, Sato EI (1993) Treatment of cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 11:487–493PubMedGoogle Scholar
  2. Bleumink GS, ter Borg EJ, Ramselaar CG, Ch Stricker BH (2001) Etanercept-induced subacute cutaneous lupus erythematosus. Rheuamtology (Oxford) 40:1317–1319CrossRefGoogle Scholar
  3. Boehm IB, Boehm GA, Bauer R (1998) Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int 18:59–62Google Scholar
  4. Bonsmann G, Schiller M, Luger TA, Stander S (2001) Terbinafine-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 44:925–931CrossRefPubMedGoogle Scholar
  5. Callen JP, Kulp-Shorten CL, Hughes AP (2001) Subacute cutaneous lupus erythematosus associated with terbinafine therapy. Arch Dermatol 137:1196–1198PubMedGoogle Scholar
  6. Callen JP, Spencer LV, Burruss JB, Holtman J (1991) Azathioprine: an effective, corticosteroids-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 127:515–522CrossRefPubMedGoogle Scholar
  7. Callen JP (2001) Therapy of cutaneous lupus erythematosus. Dermatologic Therapy 14:61–69CrossRefGoogle Scholar
  8. Crowson AN, Magro CM (1997) Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapy. Hum Pathol 28:67–73CrossRefPubMedGoogle Scholar
  9. Dalziel K, Going G, Cartwright PH, Marks R, Beveridge GW, Rowell NR (1986) Treatment of chronic discoid lupus erythematosus with an oral gold compound (Auranofin) Br J Dermatol 115:211–216PubMedGoogle Scholar
  10. Delaporte E, Catteau B, Sabbagh N, Gosselin P, Breuillard F, Doutre MS, Broly F, Piette F, Bergoend H (1997) Traitment du lupus erythemateux chronique par la sulfasalazine: 11 observations. Ann Dermatol Venereol 124:151–156PubMedGoogle Scholar
  11. Duong JD, Spigel T, Moxley RT III, Gaspari AA (1999) American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 135:1079–1087CrossRefPubMedGoogle Scholar
  12. Feldmann R, Salomon D, Saurat JH (1994) The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 189:425–427PubMedGoogle Scholar
  13. Gallego H, Crutchfield CE III, Lewis EJ, Gallego HJ (1999) Report of an association between discoid lupus erythematosus and smoking. Cutis 63:231–234PubMedGoogle Scholar
  14. Genereau T, Chosidow O, Danel C, Cherin P, Herson S (1999) High-dose intravenous immunoglobulin in cutaneous lupus erythematosus. Arch Dermatol 135:1124–1125CrossRefPubMedGoogle Scholar
  15. Goyal S, Nousari HC (2001) Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 45:142–144CrossRefPubMedGoogle Scholar
  16. Jewell ML, McCauliffe DP (2000) Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 42:983–987CrossRefPubMedGoogle Scholar
  17. Krivanek JFC, Paver WKA (1980) Further study of the use of clofazimine in discoid lupus erythematosus. Australasian J Dermatol 21:169–171Google Scholar
  18. Lagrange S, Piette JC, Becherel PA, Cacoub P, Frances C (1998) Sulfasalazine in the treatment of cutaneous lupus erythematosus: open trial in six cases. Lupus 7:21Google Scholar
  19. Lagrange S, Frances C, Roy S, Papo T, Piette JC (2004) High dose intravenous immune globulin in the treatment of refractory severe discoid lupus erythematosus. J Am Acad Dermatol, in pressGoogle Scholar
  20. Lehmann P, Holzle E, Kind P, Goerz G, Plewig G (1990) Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol 22:181–187PubMedGoogle Scholar
  21. Millard TP, Hawk JLM, McGregor JM (2000) Photosensitivity in lupus. Lupus 9:3–10CrossRefPubMedGoogle Scholar
  22. Neri R, Mosca M, Bernacchi E, Bombardieri S (1999) A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with dapsone. Lupus 8:240–243CrossRefPubMedGoogle Scholar
  23. Newton RC, Jorizzo JL, Solomon AR, Sanchez R, Bell JD, Cavallo T (1986) Mechanism-oriented assessment of isotretinoin in chronic of Subacute cutaneous lupus erythematosus. Arch Dermatol 122:180–186CrossRefPubMedGoogle Scholar
  24. Nicolas JF, Thivolet J, Kanitkis J, Lyonnet S (1990) Response of discoid and Subacute cutaneous lupus erythematosus to recombinant interferon alpha 2a. J Invest Dermatol 95:142S–145SCrossRefPubMedGoogle Scholar
  25. Nyberg F, Hassan T, Puska P, Stephansson E, Hakkinen M, Ranki A, Ros AM (1997) Occurrence of polymorphous light eruption in lupus erythematosus. Br J Dermatol 136:217–221CrossRefPubMedGoogle Scholar
  26. Ordi-Ros J, Cortes F, Cucurull E, Mauri M, Bujan S, Vilardell M (2000) Thalidomide in the treatment of cutaneous lupus erythematosus refractory to conventional therapy. J Rheumatol 27:1429–1433PubMedGoogle Scholar
  27. Pashinian N, Wallace DJ, Klinenberg JR (1998) Mycophenolate mofetil for systemic lupus erythematosus. Arthritis Rheum 41:S110CrossRefGoogle Scholar
  28. Prinz JC, Meurer M, Reiter C, Rieber EP, Plewig G, Riethmuller G (1996) Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412. J Am Acad Dermatol 34:244–252PubMedGoogle Scholar
  29. Rahman P, Gladman DD, Urowitz MB (1998) Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 25:1716–1719PubMedGoogle Scholar
  30. Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA (1985) Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 103:49–51PubMedGoogle Scholar
  31. Rodriquez-Castellanos MA, Rubio JB, Gomez JFB, Mendoza AG (1995) Phenytoin in the treatment of discoid lupus erythematosus. Arch Dermatol 131:620–621CrossRefGoogle Scholar
  32. Rudnicka L, Szymanska E, Walecka I, Stowinska M (2000) Long-term cefuroxime axetil in subacute cutaneous lupus erythematosus. A report of three cases. Dermatology 200:129–131CrossRefPubMedGoogle Scholar
  33. Ruzicka T, Meurer M, Brown-Falco O (1985) Treatment of cutaneous lupus erythematosus with etretinate. Acta Derm Venereol 65:324–329PubMedGoogle Scholar
  34. Stege H, Budde MA, Grether S, Krutmann J (2000) Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test. Photodermatol Photoimmunol Photomed 16:256–259CrossRefPubMedGoogle Scholar
  35. Tebbe B, Lauy M, Gollnick H (1992) Therapy of cutaneous lupus erythematosus with recombinant interferon alpha-2a. Eur J Dermatol 2:253–255Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 2005

Authors and Affiliations

  • Jeffrey P. Callen

There are no affiliations available

Personalised recommendations